Speculative investors and patience rarely go hand in hand. Nevertheless, if you're looking to invest in the small-cap biotech sector, patience is a requirement.

Mainz Biomed NV (NASDAQ: MYNZ - Get Free Report)'s stock price fell 5.8% during mid-day trading on Friday. The company traded as low as $0.92 and last traded at $0.9990. 283,999 shares traded hands during trading, a decline of 68% from the average session volume of 897,663 shares. The stock had previously closed at $1.06.

BERKELEY, Calif. and MAINZ, Germany, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

BERKELEY, Calif. and MAINZ, Germany, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces positive topline results from its feasibility study, examining a non-invasive blood-based screening test for the early detection of pancreatic cancer, initiated earlier this year.

BERKELEY, Calif. and MAINZ, Germany, Sept.

BERKELEY, Calif. and MAINZ, Germany, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

BERKELEY, Calif. and MAINZ, Germany, July 23, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.